Non-Invasive Monitoring Systems Aktie

Non-Invasive Monitoring Systems EBITDA

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Non-Invasive Monitoring Systems (NIMU) pr. 3. aug. 2026 er -160.000,00 USD. I foregående år var EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) -177.000,00 USD — en ændring på -9,60 % (højere).

EBITDA

-160.000,00USD

YoY

-9,60%

Senest opdateret:

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Non-Invasive Monitoring Systems er 2026 -160.000,00 USD. EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Non-Invasive Monitoring Systems var 2025 -177.000,00 USD. Det falder dermed med -9,60% højere sammenlignet med året før.
Access this data via the Eulerpool API

Non-Invasive Monitoring Systems Aktieanalyse

Hvad laver Non-Invasive Monitoring Systems? Non-Invasive Monitoring Systems Inc (NIMS) has become a major player in the field of medical diagnostics and monitoring in recent years. The company was founded in 2002 and is headquartered in Miami, Florida. Its focus is on developing and marketing innovative non-invasive technologies that enable better patient care. NIMS' business model is based on the development and marketing of products that allow for fast and accurate diagnosis of various medical conditions. These technologies can be used in various clinical areas such as intensive care, oncology, cardiology, and neurology. The company's goal is to improve patient care by making diagnostics and monitoring faster, more accurate, and more effective. NIMS has several divisions that focus on different medical applications. One of these is the gastrointestinal division, which specializes in the diagnosis and monitoring of gastrointestinal disorders. NIMS offers innovative technologies such as magnetic resonance elastography (MRE-MRI), which allows for the measurement of tissue hardness without invasive procedures. This technology is particularly used in the early detection of cancer, as it enables the detection of tissue changes at an early stage. Another important division of NIMS is cardiovascular monitoring, which aims at the early detection and monitoring of heart diseases. The company offers various non-invasive technologies for this purpose, such as wearable devices for measuring blood pressure and heart rate, or ultrasound for measuring blood flow and vascular stiffness. These technologies are intended to improve the monitoring of patients with heart diseases and to detect complications at an early stage. NIMS also offers innovative diagnostic tools for the early detection of cancer, such as the Cancer Screening Index (CSI). The CSI is a biomarker-based test that calculates the probability of developing certain types of cancer. Various factors such as family history, smoking, or age are taken into account in the calculation. The CSI aims to contribute to the early detection of cancer and thus enable better prognosis. In addition to these products, NIMS is also involved in clinical research. The company offers specialized services such as conducting clinical trials or providing expert opinions. These services are intended to promote the development of new non-invasive diagnostic and monitoring technologies and thus improve overall patient care. Overall, NIMS has become a leading company in the field of non-invasive medical diagnostics and monitoring. The company is constantly striving to advance the development of new innovative technologies to improve patient care and minimize the use of invasive procedures. With its various divisions and products, NIMS is able to cover various medical applications and thus appeal to a broad customer base. Non-Invasive Monitoring Systems er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Non-Invasive Monitoring Systems aktie

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Non-Invasive Monitoring Systems er -160.000,00 USD i 2026.

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Non-Invasive Monitoring Systems ændrede sig fra -177.000,00 USD til -160.000,00 USD, hvilket repræsenterer en ændring på -9,60 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) Non-Invasive Monitoring Systems siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

EBITDA måler driftsresultatet før virkningen af finansieringsstruktur, skattesystem og ikke-kontante afskrivninger.

EBITDA = EBIT + Af- og nedskrivninger

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s USD er en vigtig faktor for investorer. Ændringer i denne nøgletal kan signalere forbedrede eller forværrede fundamentale forhold, hvilket kan påvirke aktiekursen. På Eulerpool kan du følge EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s Non-Invasive Monitoring Systems historisk.

Access this data via the Eulerpool API

Resultatopgørelse — Non-Invasive Monitoring Systems

Alle nøgletal — Non-Invasive Monitoring Systems